RECOVERY Collaborative Group 2023, ' Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. ', Lancet (London, England), vol. 401, no. 10387, pp. 1499-1507 . https://doi.org/10.1016/S0140-6736(23)00510-X
EQUAL study investigators 2022, ' Predicting Kidney Failure, Cardiovascular Disease and Death in Advanced CKD Patients ', Kidney International Reports, vol. 7, no. 10, pp. 2230-2241 . https://doi.org/10.1016/j.ekir.2022.07.165 Kidney International Reports, 7(10), 2230-2241. ELSEVIER SCIENCE INC 2022, ' Predicting Kidney Failure, Cardiovascular Disease and Death in Advanced CKD Patients ', Kidney international reports, vol. 7, no. 10, pp. 2230-2241 . https://doi.org/10.1016/j.ekir.2022.07.165 Kidney International Reports, 7(10), 2230-2241. Elsevier Science Kidney International Reports, 7(10), 2230-2241. Elsevier Inc.
Mumford, A D & Gibbison, B J J 2022, ' Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial and updated meta-analysis ', Lancet, vol. 400, no. 10349, pp. 359-368 . https://doi.org/10.1016/S0140-6736(22)01109-6 Dimitriadis, G K 2022, ' Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial and updated meta-analysis ', Lancet, vol. 400, no. 10349, pp. 359-368 . https://doi.org/10.1016/S0140-6736(22)01109-6 RECOVERY Collaborative Group & Dark, P 2022, ' Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis ', Lancet . https://doi.org/10.1016/S0140-6736(22)01109-6
Lancet (London, England) LANCET RECOVERY Collaborative Group 2021, ' Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY) a randomised controlled, open-label, platform trial ', The Lancet, vol. 397, no. 10289, pp. 2049-2059 . https://doi.org/10.1016/S0140-6736(21)00897-7 Mumford, A D 2021, ' Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised controlled, open-label, platform trial ', Lancet, vol. 397, no. 10289, pp. 2049-2059 . https://doi.org/10.1016/S0140-6736(21)00897-7 Group, RECOVERY C & Dark, P 2021, ' Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. ', Lancet (London, England), vol. 397, no. 10289, pp. 2049-2059 . https://doi.org/10.1016/S0140-6736(21)00897-7
Journal of the American Society of Nephrology, 32(5), 1174-1186. AMER SOC NEPHROLOGY Journal of the American Society of Nephrology, 32(5), 1174-1186. American Society of Nephrology al., E 2021, ' Kidney Failure Prediction Models : A Comprehensive External Validation Study in Patients with Advanced CKD ', Journal of the American Society of Nephrology, vol. 32, no. 5, pp. 1174-1186 . https://doi.org/10.1681/ASN.2020071077 Clinical journal of the American Society of Nephrology, 32(5), 1174-1186. American Society of Nephrology J Am Soc Nephrol
RECOVERY Collaborative Group & Downey, D 2022, ' Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial ', The Lancet, vol. 399, no. 10325, pp. 665-676 . https://doi.org/10.1016/S0140-6736(22)00163-5 Mumford, A D 2022, ' Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial ', Lancet, vol. 399, no. 10325, pp. 665-676 . https://doi.org/10.1016/S0140-6736(22)00163-5 Lancet (London, England) Group, RECOVERY C, Felton, T, Dark, P & Mathioudakis, A 2022, ' Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial ', Lancet (London, England), vol. 399, no. 10325, pp. 665-676 . https://doi.org/10.1016/S0140-6736(22)00163-5
RECOVERY Collaborative Group & Downey, D 2021, ' Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial ', Lancet (London, England), vol. 397, no. 10274, pp. 605-612 . https://doi.org/10.1016/S0140-6736(21)00149-5 LANCET Mumford, A, Ramanan, A V & Gibbison, B J J & Welch, H F 2021, ' Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial ', Lancet, vol. 397, no. 10274, pp. 605-612 . https://doi.org/10.1016/S0140-6736(21)00149-5, https://doi.org/10.1016/S0140-6736(21)00149-5 The Lancet RECOVERY Collaborative Group, Felton, T, Evans, D G, Murray, C, Buch, M & Dark, P 2021, ' Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial ', Lancet (London, England), vol. 397, no. 10274, pp. 605-612 . https://doi.org/10.1016/S0140-6736(21)00149-5 2021, ' Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial ', Lancet, vol. 397, no. 10274, pp. 605-612 . https://doi.org/10.1016/S0140-6736(21)00149-5
Europe PubMed Central Lancet (London, England) RECOVERY Collaborative Group & Downey, D 2022, ' Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial ', The Lancet, vol. 399, no. 10320, pp. 143-151 . https://doi.org/10.1016/S0140-6736(21)01825-0 Group, RECOVERY C & Dark, P 2022, ' Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. ', Lancet (London, England), vol. 399, no. 10320, pp. 143-151 . https://doi.org/10.1016/S0140-6736(21)01825-0 Mumford, A D 2022, ' Aspirin in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial ', Lancet, vol. 399, no. 10320, pp. 143-151 . https://doi.org/10.1016/S0140-6736(21)01825-0